Pressmeddelande -

New Associate Partners in P.U.L.S

The board elected today two new P.U.L.S. Associate Partners, Mats Pettersson and Professor Anders Vedin

Mats Pettersson

Born 1945, B.Sc, Gothenburg School of Economics. Former CEO (2001-2007 ) and Co-founder of Biovitrum AB. Former Senior Vice President ,Mergers & Acquisitions of Pharmacia Corporation. Active mainly in CFO and business development positions and responsible for several of the transforming transactions within the Pharmacia group 1976-2001. Former Auditor 1968-1976. Vice Chairman SwedenBio, Member of the board of Lundbeck A/S, Denmark, Ablynx NV, Belgium and to-BBB in the Netherlands.

Anders Vedin

Advisor to the biotechnology and pharmaceutical industries. Professor of the Management of Medical Technologies at Chalmers University of Technology, Gothenburg, Sweden. Formerly held senior positions within the Astra group. Board member of IVA, the Royal Swedish Academy of Engineering Sciences. Chairman of CLC (UK), Cellartis AB Medivir AB and Resistentia Pharmaceuticals AB. Board member of Carlsson Research AB and Santosolve A/S (Norway).

P.U.L.S. AB Partners for Development investments in Life Sciences, P.U.L.S. AB ("PULS") was founded in 2002.

 

 

 

 

Ämnen

  • Medicinsk forskning

Kategorier

  • mats pettersson
  • anders vedin
  • p.u.l.s. ab

Kontakter

Relaterat innehåll

  • P.U.L.S. erhåller 2 miljoner kronor i anslag från NUTEK

    Inom ramen för NUTEKs utlysning “Pilotsatsning på privata företagsinkubatorer” erhåller P.U.L.S. AB 2 miljoner kronor för att stärka inkubatorn. Satsningen skall framförallt gå till att utvärdera nya arbetsmetoder för att finna nya projekt samt att fortsatt stärka arbetet med att stödja projektbolagen under dess tid i inkubatorn.

  • Tre professorer nya Associate Partners i P.U.L.S

    Den privata inkubatorn PULS utökar och breddar sin vetenskapliga bas när tre professorer inom olika områden blir Associate Partners. De nya Associate Partners är Ulf Ellervik, professor i bioorganisk kemi vid Lunds Tekniska Högskola, Anders Jeppsson professor i thoraxkirurgi, Sahlgrenska Akademin vid Göteborgs Universitet och Håkan Olsson, professor i onkologi vid Lunds Universitet.